Report cover image

Bleeding Disorders Treatment Market by Disease Type (Hemophilia A, Hemophilia B, Von Willebrand Disease), Drug Class (Antibrinolytics, Desmopressin, Fibrin Sealant), Distribution Channel - Global Forecast 2023-2030

Publisher 360iResearch
Published Oct 05, 2023
Length 191 Pages
SKU # IRE18313320

Description

Bleeding Disorders Treatment Market by Disease Type (Hemophilia A, Hemophilia B, Von Willebrand Disease), Drug Class (Antibrinolytics, Desmopressin, Fibrin Sealant), Distribution Channel - Global Forecast 2023-2030


The Bleeding Disorders Treatment Market is projected to reach USD 25.25 billion by 2030 from USD 12.42 billion in 2022, at a CAGR of 9.27% during the forecast period.

Market Segmentation & Coverage:

This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Bleeding Disorders Treatment Market.
  • Based on Disease Type, market is studied across Hemophilia A, Hemophilia B, and Von Willebrand Disease. The Hemophilia B is projected to witness significant market share during forecast period.
  • Based on Drug Class, market is studied across Antibrinolytics, Desmopressin, Fibrin Sealant, Plasma Derived Coagulation Factor Concentrates, and Recombinant Coagulation Factor Concentrates. The Antibrinolytics is projected to witness significant market share during forecast period.
  • Based on Distribution Channel, market is studied across Compounding Pharmacies, Hospital Pharmacies, and Retail Pharmacies. The Hospital Pharmacies is projected to witness significant market share during forecast period.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.
Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is an indispensable tool for assessing the Bleeding Disorders Treatment Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.

Market Share Analysis:

The Market Share Analysis offers invaluable insights into the vendor landscape Bleeding Disorders Treatment Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.

Key Company Profiles:

The report delves into recent significant developments in the Bleeding Disorders Treatment Market, highlighting leading vendors and their innovative profiles. These include Alnylam Pharmaceuticals Inc., Amgen Inc., Baxter International Inc., Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, CSL Behring, Emergent BioSolutions Inc., Grifols International, S.A., Kedrion S.p.A., Novo Nordisk A/S, Octapharma AG, Pfizer Inc., Sanofi S.A., and Xenetic Biosciences, Inc..

The report offers valuable insights on the following aspects:
  1. Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.
  2. Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.
  3. Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.
  4. Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.
  5. Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
  1. What is the market size and forecast for the Bleeding Disorders Treatment Market?
  2. Which products, segments, applications, and areas hold the highest investment potential in the Bleeding Disorders Treatment Market?
  3. What is the competitive strategic window for identifying opportunities in the Bleeding Disorders Treatment Market?
  4. What are the latest technology trends and regulatory frameworks in the Bleeding Disorders Treatment Market?
  5. What is the market share of the leading vendors in the Bleeding Disorders Treatment Market?
  6. Which modes and strategic moves are suitable for entering the Bleeding Disorders Treatment Market?


Note: PDF & Excel + Online Access - 1 Year

Table of Contents

191 Pages
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Bleeding Disorders Treatment Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increase in the prevalence of liver disorders and anemia
5.1.1.2. Rising healthcare expenditure by the government
5.1.1.3. Considerable increase in healthcare accessibility in economies
5.1.2. Restraints
5.1.2.1. Lack of skilled professionals and trained expertise
5.1.3. Opportunities
5.1.3.1. Rising awareness regarding bleeding disorders
5.1.3.2. Rise in demand due to lower infection risks and high investments in research and development
5.1.4. Challenges
5.1.4.1. High cost of medications of bleeding disorders treatment
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
5.10. Client Customization
6. Bleeding Disorders Treatment Market, by Disease Type
6.1. Introduction
6.2. Hemophilia A
6.3. Hemophilia B
6.4. Von Willebrand Disease
7. Bleeding Disorders Treatment Market, by Drug Class
7.1. Introduction
7.2. Antibrinolytics
7.3. Desmopressin
7.4. Fibrin Sealant
7.5. Plasma Derived Coagulation Factor Concentrates
7.6. Recombinant Coagulation Factor Concentrates
8. Bleeding Disorders Treatment Market, by Distribution Channel
8.1. Introduction
8.2. Compounding Pharmacies
8.3. Hospital Pharmacies
8.4. Retail Pharmacies
9. Americas Bleeding Disorders Treatment Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Bleeding Disorders Treatment Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Bleeding Disorders Treatment Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Alnylam Pharmaceuticals Inc.
13.1.2. Amgen Inc.
13.1.3. Baxter International Inc.
13.1.4. Bayer AG
13.1.5. Biogen Inc.
13.1.6. Bristol-Myers Squibb Company
13.1.7. CSL Behring
13.1.8. Emergent BioSolutions Inc.
13.1.9. Grifols International, S.A.
13.1.10. Kedrion S.p.A.
13.1.11. Novo Nordisk A/S
13.1.12. Octapharma AG
13.1.13. Pfizer Inc.
13.1.14. Sanofi S.A.
13.1.15. Xenetic Biosciences, Inc.
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us